Tel: 0113 4264300 | info@arterius.co.uk

PRODUCTS

PRODUCTS

Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to match the ease of delivery of Bare Metal Stent (BMS) and Drug Eluting Stent (DES); come in a range of sizes and lengths; Provide equivalent mechanical performance (radial strength) to the best-in-class DES products.
Read More…

ABOUT

ABOUT

Founded in 2009, Leeds-based Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile.
The founding directors have significant experience in the development of medical devices and in the cardiovascular devices field in particular. Read More…

WHAT WE DO

WHAT WE DO

Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile. Arterius has recently completed the pre-clinical trials and, on the back of these, believes that this collaboration has delivered a next generation drug eluting fully biodegradable stent with a market leading profile. Read More…

Latest News

Arterius Appoints Stever Parker as new Chief Executive Officer

ARTERIUS PRESS RELEASE

Date: 1st March 2022

Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Steve Parker as Chief Executive Officer. In the role Steve will lead the next phase of developing and scaling the business as it moves closer to commercialization of it’s suite of innovative and novel medical products.

Arterius was founded in 2009 and has developed a series of technologies including a next-generation bioresorbable cardiovascular scaffold (stent) with a market-leading clinical profile. Arterius has recently completed the pre-clinical trials and, on the back of these, believes that this collaboration has delivered a next generation drug eluting fully biodegradable stent. This technology is now being evaluated in this first application in human trials.

Steve brings a wealth of leadership and commercial experience and has held a series of senior roles in International medical device companies over a period of over 40 years. Most recently he served as Chief Executive Officer of Midlands based Creavo Medical Technologies which he led and grew from start up through various international funding rounds and taking products through European and US regulatory pathways. He joined Creavo from Abbott Laboratories Point of Care Division where he held divisional commercial responsibility for all global markets outside of North America, significantly growing the profile of point of care technologies across multiple geographies. Previously he has held progressively more senior roles at global implantable device business St Jude Medical (now part of Abbott Laboratories) and Cardiology pioneer Marquette Electronics (later to become part of GE Healthcare).

Steve will build on the success of Kadem Al-Lamee, co-founder and CEO for the over the last 12 years of Arterius who will become Chief Technology Officer leading the development of the existing product pipeline and IP and of new applications and technologies.

Steve Parker Chief Executive Officer commented: – “I am delighted to be joining the team at Arterius at such a critical time. This is a highly innovative company with technologies that could drive real change in global healthcare. The innovation achieved so far is truly outstanding and has significant potential to aid clinicians in the treatment of coronary and vascular disease and ultimately bring a better quality of life to patients all over the world.”

Chris Meredith Chairman of Arterius said: – “ I want to welcome Steve to Arterius as he brings a wealth of leadership experience in the medical devices industry as well as experience of growing and funding innovative companies introducing new technologies. His expertise will be invaluable as Arterius continues its journey through clinical trials and move ever closer to commercialization.”

END
To learn more visit: www.arterius.co.uk

For further information:
Arterius Ltd.
Steve Parker, CEO
+44(0) 113 426 4300

steve.parker@arterius.co.uk